Skip to main content
Publish date:

Thursday's Winners & Losers: Durect

Shares shoot up 19% after earnings.

Handset maker



gained 23 cents, or 4.1%, to $5.86 following a presentation by the company's Chief Financial Officer Andrew Brown to investors at the Merrill Lynch Technology 2008 conference.

Brown said the company's Centro phone introduced about eight months ago is bringing a new demographic of customers and its performance is meeting the company's expectations. He said Palm also plans to refresh its Windows Mobile based phones this summer. And he said the company has a new platform coming out later this year and will deliver the first products based on that platform in 2009.



plunged $1.46, or 9%, to $14.76 after Michael Rollins, an analyst at Citigroup, downgraded the stock to sell from hold, saying the stock trades at a "substantial" premium to his fair value estimate of $13 a share. Clearwire said Wednesday it will combine with Sprint Nextel to form a $14.5 billion wireless broadband company.

Specialty pharmaceutical company


(DRRX) - Get DURECT Corporation Report

shot up 73 cents, or 19.2%, to $4.53 on Thursday. Its recent quarter benefitted from better expense-revenue alignment. The company met analysts' expectations and narrowed its loss in the recent quarter to $7.8 million, or 11 cents a share, from a loss of $8.8 million, or 13 cents a share a year prior. Revenue increased 12% to $6.4 million.

TheStreet Recommends

Shares of

Gibraltar Industries

(ROCK) - Get Gibraltar Industries, Inc. Report

, which makes residential and commercial building products, soared 28% to $14.12. The Buffalo, N.Y., firm posted first-quarter earnings of $6.7 million, or 22 cents a share, vs. $6.2 million, or 21 cents a share, a year ago. Analysts surveyed by Thomson Reuters were expecting 14 cents a share.

Niwot, Colo.'s


(CROX) - Get Crocs, Inc. Report

, a footwear concern, added 17% to $11.60. The company reported non-GAAP first-quarter earnings of $7.6 million, or 9 cents a share, slightly behind the consensus estimate of 10 cents a share. Crocs also reaffirmed full-year guidance for EPS between $1.70 and $1.80, ahead of the Street's prediction of $1.60.



(BCRX) - Get BioCryst Pharmaceuticals, Inc. Report

reported a loss of $13.1 million, or 34 cents a share, widened from a loss of $8.8 million, and 30 cents a share in the year-ago quarter. Revenue rose to $10.8 million, from $9.2 million, but fell far below analysts' estimates of a loss of 18 cents a share, on revenue of $19.8 million. Shares were down 24 cents, or 7.6%, at $2.91.

This article was written by a staff member of